Search clinical trials for: Besivance

Total 48 results

Brett King
Swedish Orphan Biovitrum

Terminated

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

United States
St. Jude Children's Research Hospital

Completed

Dose Escalation Study Of Palifermin in Pediatric Research Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation | Oral Mucositis

United States
Swedish Orphan Biovitrum

Completed

PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

Multiple Myeloma | Non-Hodgkin's Lymphoma
Copenhagen University Hospital at Herlev

Completed

Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective? (CES)

Frail Older Adults

Denmark
University Hospital Heidelberg
ZOLL Circulation, Inc., USA

Unknown

Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE) (HAIS-SE)

Ischemic Stroke | Hypothermia | Thrombolysis

Germany
Bispebjerg Hospital
Malmö University

Completed

Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)

Cerebral Infarction

Denmark
Swedish Orphan Biovitrum

Completed

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

Leukemia

United States
Swedish Orphan Biovitrum

Completed

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

Multiple Myeloma

Germany
Bausch & Lomb Incorporated

Completed

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Bacterial Conjunctivitis

United States
Bausch & Lomb Incorporated

Terminated

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis

United States
Bausch & Lomb Incorporated

Completed

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis

United States
Cambridge University Hospitals NHS Foundation Trust

Terminated

Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis (CAM-THY)

Multiple Sclerosis

United Kingdom
Swedish Orphan Biovitrum

Completed

Palifermin DDI (Drug Drug Interaction)

Healthy Volunteers
Bausch & Lomb Incorporated

Completed

A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.

Acute Bacterial Conjunctivitis
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Mucositis | Stomatitis | Solid Tumors | Squamous Cell Carcinoma
Rutgers, The State University of New Jersey
Bausch & Lomb Incorporated

Completed

Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children

Congenital Nasolacrimal Duct Obstruction

United States
University Hospital Southampton NHS Foundation...

Completed

A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients

Bronchial Asthma

United Kingdom
Bausch & Lomb Incorporated

Terminated

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Bacterial Conjunctivitis

United States
Frank A. Bucci, Jr., M.D.

Completed

Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification

Cataracts

United States
Cairo University

Completed

Evaluation of Air Abrasion Surface Pretreatment in the Repairing Capacity of Defective Composite Restoration

Repair

Egypt
Bausch & Lomb Incorporated

Completed

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation

Healthy

United States
John, George, M.D.
Bausch & Lomb Incorporated

Completed

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

Blepharitis

United States
Instituto de Oftalmología Fundación Conde de Valenciana

Completed

Effect of Topical Besifloxacin on Ocular Surface Bacterial Microbiota Prior to Cataract Surgery

Cataract Senile | Microbial Disease

Mexico
Johns Hopkins University

Completed

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Cataract Extraction

United States
Swedish Orphan Biovitrum
Amgen

Completed

Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Lung Cancer | Dysphagia
Children's Oncology Group
National Cancer Institute (NCI)

Withdrawn

Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant

Malignant Neoplasm | Gastrointestinal Mucositis
Martin, Paul
National Cancer Institute (NCI)

Completed

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma and other conditions

United States
Bausch & Lomb Incorporated

Completed

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Cataract Extraction

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma

Multiple Myeloma | Mucositis

United States
Ophthalmology Consultants, Ltd.
Bausch & Lomb Incorporated; Ophthalmology Associates, St Louis

Completed

2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery (STB-01)

Cataract Surgery | Corneal Health

United States
Sherif S. Farag

Terminated

Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplasia

United States
Swedish Orphan Biovitrum
Amgen

Completed

Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)

Lymphoma | Leukemia | Cancer
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Lymphoma

United States
Swedish Orphan Biovitrum
Amgen

Completed

Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation

Hematologic Malignancies | Graft Versus Host Disease
Cornea Consultants Of Nashville
Bausch & Lomb Incorporated; SCRI Development Innovations, LLC

Terminated

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (Eye02)

Corneal Ulcers

United States
M.D. Anderson Cancer Center

Completed

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Lymphoma | Leukemia | Myeloma

United States
Columbia University

Terminated

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB) (RDEB)

Epidermolysis Bullosa

United States
M.D. Anderson Cancer Center

Completed

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Myeloma

United States
M.D. Anderson Cancer Center

Completed

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Lymphoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

T-cell Non-Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Withdrawn

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Myeloma
Montefiore Medical Center
Nationwide Children's Hospital; Children's Hospital Los Angeles

Terminated

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Solid Tumor | Allogeneic Hematopoietic Stem Cell Transplantation | Neuroepithelial Tumor

United States
M.D. Anderson Cancer Center

Withdrawn

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Lymphoma
M.D. Anderson Cancer Center
Celgene Corporation

Terminated

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hematopoietic Cell Transplantation Recipient

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Plasma Cell Myeloma | Plasma Cell Leukemia in Remission

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States

3

Subscribe